EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023

Berlin, March 22, 2024 - Eckert Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26.

In the Medical segment, sales rose by € 24.3 million or 27% to € 115.2 million compared to the previous year. The increase in sales was driven in particular by strong demand for radiopharmaceuticals. At € 130.9 million, sales in the Isotope Products segment remained at the previous year's level (€ 131.4 million).

For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT before special items from continuing operations of around € 50 million.

The full 2023 financial statements can be found here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz23e.pdf

About Eckert Ziegler.
Eckert Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

For enquiries please contact:
Eckert Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com